OnKure Therapeutics Files Q1 2025 10-Q
Ticker: OKUR · Form: 10-Q · Filed: May 6, 2025 · CIK: 1637715
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
OnKure Therapeutics filed its Q1 2025 10-Q. Financials updated.
AI Summary
OnKure Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Reneo Pharmaceuticals, Inc. until a name change on March 25, 2015, reported financial data for the first quarter of 2025. Key financial items include Additional Paid-In Capital and Retained Earnings as of December 31, 2024, and March 31, 2025, respectively.
Why It Matters
This filing provides investors with an update on OnKure Therapeutics' financial position and operational performance for the first quarter of 2025, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, OnKure Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-12-31 — Previous Year End Date (Provides a comparative point for financial performance.)
Key Players & Entities
- OnKure Therapeutics, Inc. (company) — Filer of the 10-Q
- Reneo Pharmaceuticals, Inc. (company) — Former name of OnKure Therapeutics
- March 31, 2025 (date) — End of the reporting period
- March 25, 2015 (date) — Date of company name change
FAQ
What were the primary financial activities of OnKure Therapeutics during the first quarter of 2025?
The filing indicates financial activities related to 'AdditionalPaidInCapitalMember' and 'GeneralAndAdministrativeExpenseMember' for the period of January 1, 2025, to March 31, 2025.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for OnKure Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When did the company change its name from Reneo Pharmaceuticals, Inc.?
The company changed its name from Reneo Pharmaceuticals, Inc. on March 25, 2015.
What is the business address and phone number listed for OnKure Therapeutics?
The business address is 6707 Winchester Circle, Suite 400, Boulder, CO 80301, and the phone number is (720) 307-2892.
Does the filing mention any merger agreements?
Yes, the filing references 'MergerAgreementMember' in relation to common stock and restricted stock units, with dates of October 4, 2024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding OnKure Therapeutics, Inc. (OKUR).